Although there have yet to be any FDA-approved drugs targeting NRF2 activity in cancer, there have been increasing efforts toward the development of novel NRF2 inhibitors 73 and continued research in this area has great potential for clinical application. This evidence concerns the gene NFE2L2 and cancer.